Department of Health Ministers have carefully considered all the representations received during consultation and have decided the following technology appraisals should be added to NICE’s work programme:
Cetuximab for colorectal cancer
To appraise the clinical and cost effectiveness of cetuximab for second and third line treatment of metastatic colorectal cancer following the failure of oxaliplatin-inducing chemotherapy.
Cetuximab for head and neck cancer
To appraise the clinical and cost effectiveness of cetuximab within its licensed indication in combination with platinum-based chemotherapy for metastatic and/or recurrent squamous cell carcinoma of the head and neck
IMRT for head and neck cancer
To appraise the clinical and cost effectiveness of intensity modulated radiotherapy for the treatment of head and neck cancer
IMRT for breast cancer
To appraise the clinical and cost effectiveness of intensity modulated radiotherapy for the treatment of breast cancer
IMRT for prostate cancer
To appraise the clinical and cost effectiveness of intensity modulated radiotherapy for the treatment of prostate cancer

Improve our website by taking part in a short online survey.
Contact details for obtaining hard-copy DH publications.

Useful tips to ensure you get the most from PDFs and the free Reader program. Topics covered include accessibility, troubleshooting and searching files.